Amkay Products

Which are the latest news on Amkay Products?

Why is Amkay Products Ltd falling/rising?

As of 05-Sep, Amkay Products Ltd's stock price is Rs 49.00, down 4.95%, reflecting a significant decline over various periods, including a year-to-date drop of 20.65%. The stock is underperforming its sector and trading below key moving averages, with low investor participation further exacerbating the downward trend.

As of 05-Sep, Amkay Products Ltd is experiencing a decline in its stock price, currently at Rs 49.00, which reflects a change of -2.55 (-4.95%). This drop is part of a broader trend, as the stock has underperformed significantly over various periods, including a 1-week decline of -14.04% compared to a minor decrease of -0.97% in the Sensex. Year-to-date, the stock has fallen by -20.65%, while the Sensex has only decreased by -10.21%.<BR><BR>Today's performance indicates that the stock has underperformed its sector by -1.41%. It reached an intraday low of Rs 49, marking a decrease of -4.95% for the day. Additionally, Amkay Products is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend. <BR><BR>Investor participation has also declined, with a delivery volume of 0 on September 3, indicating a -100% drop against the 5-day average delivery volume. This lack of trading activity further contributes to the stock's downward pressure. Overall, the combination of poor performance relative to the sector, low investor participation, and trading below moving averages are key factors contributing to the decline in Amkay Products Ltd's stock price.

What does Amkay Products do?

Amkay Products Ltd is a micro-cap company in the healthcare services industry, recently converted to a public limited company in August 2023. It has a market cap of INR 49 Cr, with key metrics including a P/E ratio of 22.00 and a debt-equity ratio of 0.03.

Overview: <BR>Amkay Products Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Amkay Products Limited was originally incorporated as "Amkay Products Private Limited" in 2007. It was converted into a Public Limited Company and renamed on August 28, 2023. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 49 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 22.00 <BR>Industry P/E: 112 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.03 <BR>Return on Equity: 8.76% <BR>Price-to-Book: 1.87<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Amkay Products?

Amkay Products' peers include Aspira Pathlab, Royal Sense, Shree Pacetronix, KMS Medisurgi, N G Industries, Centenial Surgic, Bandaram Pharma, and Deccan Healthcar. Management risk varies from excellent at Royal Sense to below average at several others, with growth and capital structure ratings also differing among peers.

Peers: The peers of Amkay Products are Aspira Pathlab, Royal Sense, Shree Pacetronix, KMS Medisurgi, N G Industries, Centenial Surgic, Bandaram Pharma, and Deccan Healthcar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Royal Sense and N G Industries, while Good management risk is found at Shree Pacetronix and Amkay Products, and Average management risk is present at KMS Medisurgi. Below Average management risk is noted at Aspira Pathlab, Centenial Surgic, Bandaram Pharma, and Deccan Healthcar. Growth is Excellent at Royal Sense and Bandaram Pharma, Good at Shree Pacetronix and Amkay Products, while Below Average growth is seen at Aspira Pathlab, KMS Medisurgi, N G Industries, and the rest. Average capital structure is found at Aspira Pathlab and Centenial Surgic, while Good capital structure is noted at Royal Sense, Shree Pacetronix, Amkay Products, KMS Medisurgi, and N G Industries, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aspira Pathlab at 41.50%, while the lowest is Royal Sense at -62.36%. Amkay Products does not have a 1-year return available for comparison. Additionally, KMS Medisurgi and N G Industries have negative six-month returns.

How big is Amkay Products?

As of 10th June, Amkay Products Ltd has a market capitalization of 48.00 Cr, classifying it as a Micro Cap company. There is no valid financial data available for the latest four quarters, but as of March 2025, Shareholder's Funds are 24.07 Cr and Total Assets are 29.63 Cr.

As of 10th June, <BR><BR>Market Cap: Amkay Products Ltd has a market capitalization of 48.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 24.07 Cr and Total Assets valued at 29.63 Cr.

When is the next results date for Amkay Products Ltd?

The next results date for Amkay Products Ltd is 28 May 2026.

The next results date for Amkay Products Ltd is scheduled for 28 May 2026.

How has been the historical performance of Amkay Products?

Amkay Products has shown fluctuating performance over the past five years, with net sales increasing to 38.39 Cr in March 2025 from 31.07 Cr in March 2024, alongside improvements in profits and total assets, indicating a positive trend in recent years.

Answer:<BR>The historical performance of Amkay Products shows a fluctuating trend in net sales and profits over the past five years.<BR><BR>Breakdown:<BR>Amkay Products reported net sales of 38.39 Cr in March 2025, an increase from 31.07 Cr in March 2024 and 27.86 Cr in March 2023, although it was lower than the 40.70 Cr in March 2021. The total operating income followed a similar pattern, reaching 38.39 Cr in March 2025. The company's total expenditure, excluding depreciation, was 34.26 Cr in March 2025, up from 27.74 Cr in March 2024. Operating profit (PBDIT) increased to 5.45 Cr in March 2025 from 4.58 Cr in March 2024, while profit before tax rose to 4.30 Cr in March 2025 from 3.50 Cr in March 2024. Profit after tax also improved to 3.34 Cr in March 2025 compared to 2.63 Cr in March 2024. The company's total assets increased to 29.63 Cr in March 2025 from 17.74 Cr in March 2024, with total liabilities also rising to 29.63 Cr. The cash flow from financing activities showed a positive trend with a net cash inflow of 1.00 Cr in March 2025, indicating improved liquidity. Overall, while Amkay Products experienced some fluctuations, the recent years show a positive trajectory in sales and profitability.

Is Amkay Products overvalued or undervalued?

As of September 15, 2025, Amkay Products is considered undervalued with a PE ratio of 13.61 and an EV to EBITDA of 11.27, making it more attractive compared to its peers, despite a year-to-date stock performance decline of -15.87% against the Sensex's 4.67% return.

As of 15 September 2025, the valuation grade for Amkay Products has moved from very expensive to very attractive, indicating a significant shift in its market perception. The company is currently assessed as undervalued. Key ratios supporting this conclusion include a PE ratio of 13.61, an EV to EBITDA of 11.27, and a ROE of 13.88%. <BR><BR>In comparison to its peers, Amkay Products stands out with a much lower PE ratio than Poly Medicure (56.25) and Blue Jet Health (34.63), both categorized as very expensive. This suggests that Amkay Products offers a more favorable valuation relative to its competitors. Despite a recent decline in stock performance compared to the Sensex, where it has underperformed with a year-to-date return of -15.87% against the Sensex's 4.67%, the underlying financial metrics indicate that the company is positioned well for potential growth.

Who are the top shareholders of the Amkay Products?

The top shareholder of Amkay Products is Kashyap Pravin Mody, holding 30.95%, with no pledged promoter holdings. The highest public shareholder is Rakesh Khanna at 1.11%, while individual investors collectively own 23.23% of the shares.

The top shareholders of Amkay Products primarily consist of the promoters, with Kashyap Pravin Mody holding the highest stake at 30.95%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Rakesh Khanna, who owns 1.11% of the shares. Additionally, individual investors collectively hold 23.23% of the company's shares.

What is the technical trend for Amkay Products?

As of May 29, 2025, Amkay Products is in a mildly bearish trend, indicated by daily moving averages and weekly Bollinger Bands, despite a mildly bullish weekly MACD and mixed signals from Dow Theory, with the stock underperforming relative to the Sensex.

As of 29 May 2025, the technical trend for Amkay Products has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating bearish momentum and the weekly Bollinger Bands also reflecting a bearish outlook. The weekly MACD shows a mildly bullish signal, but this is countered by the overall bearish sentiment from the daily indicators. The Dow Theory presents a mixed view with a mildly bearish weekly signal and a mildly bullish monthly signal. The stock's performance relative to the Sensex shows significant underperformance across multiple time frames, further supporting the bearish outlook.

Has Amkay Products declared dividend?

No Dividend History Available